Thursday, August 18, 2011 7:27:23 PM
no problem here is a good one , now keep in mind what i said b4,a p to e is based on any earnings number past present or future, refrence the current price.
just calculating the p to e is nothing, you want to verfy that it is worth that and will continue that p to e number.
so without peg orypeg, your company wont be allowed to keep its current p to e of 10, you have to have the growth in the future to back up your current valuation
The PEG and YPEG
Two commonly used applications of the P/E ratio are the P/E and growth ratio (PEG) and the year-ahead P/E and growth ratio (YPEG).
The PEG simply takes the annualized rate of growth out to its furthest estimate, then compares this with the trailing P/E ratio. Since future growth makes a company more valuable, it makes sense that higher growth rates should increase a company's valuation. Relying solely on a trailing P/E in this regard would be like trying to drive with your eyes fixed on the rearview mirror.
For instance, if a company is expected to grow at 10% a year over the next two years, and it has a P/E of 10, it will have a PEG of 1.
10 trailing P/E / 10% projected EPS growth rate = 1.0 PEG
The lower the PEG ratio, the more cheaply a company is valued. If the company in the above example only had a P/E of 5, but was expected to grow at 10% a year, it would have a PEG of 0.5. If the company had a P/E of 20 and expected growth of 10% a year, it would have a PEG of 2.
While the PEG is most often used for growth companies, the YPEG is best suited for valuing larger, more-established ones. The YPEG uses the same assumptions as the PEG, but it looks at different numbers. Rather than basing the P/E ratio on trailing earnings, it compares the stock price to earnings estimates for the year ahead. It then uses estimated five-year growth rates, which are readily available from several quote sources. Thus, if the forward P/E is 10, and analysts expect the company to grow at 20% over the next five years, the YPEG is equal to 0.5.
Fools should view the PEG and YPEG in the context of other measures of value, rather than considering them magic money machines.
Multiples
Rather than trying to look at growth rates, many investors simply look at estimated forward earnings, then guess what fair multiple someone might pay for the stock. For example, suppose XYZ Corp. has historically traded at about 10 times earnings, and it's currently down to 7 times earnings because it missed estimates one quarter. If the missed quarter was just a short-term anomaly, it would be reasonable to expect that the stock will return to its historic 10 times multiple.
When you project fair multiples for a company based on forward earnings estimates, you start to make a heck of a lot of assumptions about what that company will do in the future. With enough research, you can reduce the risk of being wrong, but it will always still exist. Should one of your assumptions prove incorrect, the stock probably won't go where you'd expect it to. That said, most of the other investors and companies out there are using this same approach, making their own assumptions as well. In such a worst-case scenario, at least you won't be alone.
In a modification to the multiple approach, you can also determine the relationship between the company's P/E and the average P/E of the S&P 500. If XYZ Corp. has historically traded at 150% of the S&P 500, and the S&P is currently at 10, many investors believe that XYZ Corp. should eventually hit a fair P/E of 15, assuming that nothing changes. This historical relationship requires some sophisticated databases and spreadsheets to figure out, and it's more often used by professional money managers than individual investors.
my head hurts really really hurts
the dr
just calculating the p to e is nothing, you want to verfy that it is worth that and will continue that p to e number.
so without peg orypeg, your company wont be allowed to keep its current p to e of 10, you have to have the growth in the future to back up your current valuation
The PEG and YPEG
Two commonly used applications of the P/E ratio are the P/E and growth ratio (PEG) and the year-ahead P/E and growth ratio (YPEG).
The PEG simply takes the annualized rate of growth out to its furthest estimate, then compares this with the trailing P/E ratio. Since future growth makes a company more valuable, it makes sense that higher growth rates should increase a company's valuation. Relying solely on a trailing P/E in this regard would be like trying to drive with your eyes fixed on the rearview mirror.
For instance, if a company is expected to grow at 10% a year over the next two years, and it has a P/E of 10, it will have a PEG of 1.
10 trailing P/E / 10% projected EPS growth rate = 1.0 PEG
The lower the PEG ratio, the more cheaply a company is valued. If the company in the above example only had a P/E of 5, but was expected to grow at 10% a year, it would have a PEG of 0.5. If the company had a P/E of 20 and expected growth of 10% a year, it would have a PEG of 2.
While the PEG is most often used for growth companies, the YPEG is best suited for valuing larger, more-established ones. The YPEG uses the same assumptions as the PEG, but it looks at different numbers. Rather than basing the P/E ratio on trailing earnings, it compares the stock price to earnings estimates for the year ahead. It then uses estimated five-year growth rates, which are readily available from several quote sources. Thus, if the forward P/E is 10, and analysts expect the company to grow at 20% over the next five years, the YPEG is equal to 0.5.
Fools should view the PEG and YPEG in the context of other measures of value, rather than considering them magic money machines.
Multiples
Rather than trying to look at growth rates, many investors simply look at estimated forward earnings, then guess what fair multiple someone might pay for the stock. For example, suppose XYZ Corp. has historically traded at about 10 times earnings, and it's currently down to 7 times earnings because it missed estimates one quarter. If the missed quarter was just a short-term anomaly, it would be reasonable to expect that the stock will return to its historic 10 times multiple.
When you project fair multiples for a company based on forward earnings estimates, you start to make a heck of a lot of assumptions about what that company will do in the future. With enough research, you can reduce the risk of being wrong, but it will always still exist. Should one of your assumptions prove incorrect, the stock probably won't go where you'd expect it to. That said, most of the other investors and companies out there are using this same approach, making their own assumptions as well. In such a worst-case scenario, at least you won't be alone.
In a modification to the multiple approach, you can also determine the relationship between the company's P/E and the average P/E of the S&P 500. If XYZ Corp. has historically traded at 150% of the S&P 500, and the S&P is currently at 10, many investors believe that XYZ Corp. should eventually hit a fair P/E of 15, assuming that nothing changes. This historical relationship requires some sophisticated databases and spreadsheets to figure out, and it's more often used by professional money managers than individual investors.
my head hurts really really hurts
the dr
Recent KBLB News
- The End of Performance at Any Cost, as Spider Silk Points to a Cleaner Future • GlobeNewswire Inc. • 04/15/2026 01:15:00 PM
- Advanced Materials Science 2026: How Spider Silk, Carbon Fiber & Aerogels are Powering Medicine, Defense & Space Tech Today • GlobeNewswire Inc. • 04/14/2026 01:20:00 PM
- From Milestone to Momentum: Kraig Biocraft Leadership Travels to South East Asia Following Record-Setting 1.3 Metric Ton Recombinant Spider Silk Cocoon Production Cycle • GlobeNewswire Inc. • 04/13/2026 11:05:00 AM
- From Genetic Puzzle to Industrial Platform • GlobeNewswire Inc. • 04/08/2026 01:31:34 PM
- Why Advanced Materials Are Reshaping the Industrial Ecosystem • GlobeNewswire Inc. • 04/07/2026 01:15:00 PM
- The intersection of biotechnology, advanced materials, and molecular biology • IH Market News • 04/07/2026 06:56:44 AM
- Spider Silk Has Been a Lab Curiosity for Decades; One Company Just Produced Over a Ton of It in a Single Month • AllPennyStocks.com • 04/06/2026 05:06:15 PM
- Kraig Biocraft Laboratories Shatters Production Record, Delivering Over 1.3 Metric Tons of Spider Silk Cocoons in a Single Month, A 5X Increase Over Previous High • GlobeNewswire Inc. • 04/06/2026 11:05:00 AM
- From Lab Fiber to Luxury Fabric: Kraig Biocraft Laboratories Targets Apparel First with Engineered Spider Silk • GlobeNewswire Inc. • 04/02/2026 01:05:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:38:14 PM
- Kraig Biocraft Laboratories Deploys Over 700,000 BAM-1 Alpha Production Hybrids, Achieving Key Milestone in its Aggressive Scale-Up Plan • GlobeNewswire Inc. • 03/30/2026 11:05:00 AM
- Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics • GlobeNewswire Inc. • 03/23/2026 11:05:00 AM
- Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale • GlobeNewswire Inc. • 03/18/2026 12:51:04 PM
- 24/7 Market News: Kraig Labs the Bootstrapped Unicorn in the Making • GlobeNewswire Inc. • 03/11/2026 01:15:00 PM
- Washington’s Textile Strategy: How DPA Title III Could Strengthen U.S. Manufacturing and Defense Supply Chains • GlobeNewswire Inc. • 03/05/2026 03:05:00 PM
- Kraig Biocraft Laboratories Targets New Industrial and Defense Biomaterials as "Project Atlas" Hits Major Milestone • GlobeNewswire Inc. • 03/05/2026 12:05:00 PM
- Defense Supply Chains and Strategic Materials Drive the Morning Bid • GlobeNewswire Inc. • 03/03/2026 02:51:45 PM
- Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength • GlobeNewswire Inc. • 02/27/2026 02:45:46 PM
- Biotech and Big Tech Drive the Morning Narrative • GlobeNewswire Inc. • 02/24/2026 03:17:14 PM
- 24/7 Market News- “Somewhere in Michigan”: National Geographic Spotlights Kraig Biocraft Laboratories Science Powering Recombinant Spider Silk Production • GlobeNewswire Inc. • 02/24/2026 01:05:00 PM
- Biotech Breakthroughs, Big Buyouts, Immunotherapy Momentum, and a Media Megamerger • GlobeNewswire Inc. • 02/23/2026 02:36:14 PM
- Kraig Biocraft Laboratories’ Spider Silk Advancements Featured as the Cover of National Geographic's March 2026 Issue • GlobeNewswire Inc. • 02/23/2026 12:05:00 PM
- $30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum • GlobeNewswire Inc. • 02/19/2026 04:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 04:17:09 PM
- 24/7 Market News- It’s Not Synthetic, It’s Real. Kraig Labs Nears Spider Silk Breakthrough • GlobeNewswire Inc. • 02/18/2026 01:45:00 PM
